Phoenix Asia Holdings is no longer being priced as a Hong Kong foundation contractor. In May the Cayman listing signed a stock purchase pact to absorb ACEA Pharma, a clinical-stage oncology and autoimmune developer sitting inside the Scilex orbit, by issuing one hundred million new ordinary shares at an agreed $10 each. That issuance, if it ever completes, hands ACEA Therapeutics about eighty-two percent of the go-forward company and leaves today's public holders as a thin minority in a renamed pharmaceutical vehicle. Construction still produces the only revenue on the books. The equity is a call on a reverse takeover that has been announced and not closed.
The contractor underneath that story just finished a year in which sales barely held near $7 million while gross profit collapsed from the prior year's high-twenties margin into the mid-single digits. Operating income flipped from a profit to a loss of more than $1 million, and cash finished the year below $1 million as receivables and deposits absorbed the listing proceeds. A zero-coupon convertible note of $20 million was issued the same day as the ACEA pact to the controlling shareholder, Phoenix Prosperity, as payment for advisory services rather than as fresh cash. The note converts at the same $10 reference used to value the target. The construction print is what the market is being asked to ignore while it capitalizes a deal that has not closed.
The annual filing arrived two weeks late after a July notification, still showing unremediated control weaknesses and a customer book in which five names supply nearly all sales. No closing notice has appeared since the May agreement, even though the parties had pointed to a late-spring completion. The equity now capitalizes at more than $400 million against book value of about $6 million. The debate is whether that price is an option on a completed reverse takeover or a construction residual that the market refuses to mark to the income statement.